Integra LifeSciences Holdings Corporation

Good day. Thank you for standing by. Welcome to Integral Life Sciences' third quarter 2024 financial results conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automatic message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to your speaker host, Chris Ward, Senior Director of Investor Relations. Please go ahead.

Good morning, and thank you for joining the Integral Life Sciences Third Quarter 2024 Earnings Conference Call. With me on the call are Stuart Essek, Executive Chairman, Jan DeWitt, President and Chief Executive Officer, and Leah Knight, Chief Financial Officer. Earlier this morning, we issued a press release announcing our Third Quarter 2024 financial results. The release and corresponding earnings presentation, which will be referenced during the call, are available at Integralife.com under Investor Events and Presentations in a file named Third Quarter 2024 Earnings Call Presentations. Before we begin, I would like to remind you that many of the statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act report filed with the SEC and in the release. Also in our prepared remarks, we will reference reported and organic revenue and organic revenue growth excluding Boston. Organic revenue growth excludes the effects of foreign currency, acquisitions, and divestiture. Organic revenue growth excluding Boston excludes revenues from products manufactured in our Boston facility in both periods. Management believes that excluding revenue from all products manufactured at the Boston plant through the third quarter provides useful information when evaluating the company's organic growth because of the unusual nature of the manufacturing stoppage and voluntary global recall impact. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures can be found in today's press release, which is an exhibit to Integra's current report on Form 8-K, filed today with the SEC. And with that, I would like to turn the call over to Stuart.

Thank you, Chris, and good morning, everyone. I am pleased today to announce the appointment of Mojda Pol as Integra's next CEO and to discuss our leadership transition. I'd like to start by thanking Jan for his leadership and contributions over the last three years and for his commitment to ensuring a seamless transition. During his tenure, Jan made a number of significant contributions and faced several difficult challenges. His hard work, dedication, and professionalism have been constant throughout. Under his leadership, we grew our international business significantly and added a number of digital innovations to our product pipeline. We executed two important acquisitions, Durazorb, which added an important synthetic product to our breast reconstruction pipeline, and more recently, Aclarent, cementing our entry into the ear, nose, and throat market. In addition, one of Jan's most important contributions has been his ability to recruit top talent to the company. His focus on building strong, capable teams will leave a lasting impact on Integra. While many challenges remain, Jan's efforts have laid the groundwork for our future success. Thank you, Jan. On behalf of myself, the board, and all of our employees, I wish you well. I am also delighted that Mojda Pol will be joining us as Integra's next president and CEO in January. Before sharing details on Mojda's background, I want to underscore that the CEO search process was thorough and competitive, and the opportunity attracted a number of impressive candidates. Mojda is an accomplished healthcare executive with almost three decades of extensive experience leading global businesses and operations in complex multinational organizations. She has a proven track record of delivering growth and performance through operational excellence, portfolio transformation, value-creating innovation, and impactful capital allocation. Throughout her career, Mojda has successfully led business strategy, global operations, R&D, commercial execution, and M&A. Mojda served in several leadership positions at 3M Company, including most recently Group President of Healthcare, an $8.5 billion global business. Prior to 3M, Mojda held leadership roles of increasing responsibility with Medtronic and Boston Scientific. She has also served on the board of directors of Align Technology, iRhythm Technologies, and Stanley Black & Decker. Throughout her career, Mojda has built and led high performing teams across different functions, businesses, and geographies. Her product experience spans Integra's markets, including wound care, neurosurgery, and digital medical technologies. The board and I have enjoyed getting to know Mojda well through this process, and we are very confident she will further strengthen our foundation and usher in our next chapter of innovation, growth, and shareholder value creation. She joins us at a critical juncture in the company's history and is the right leader to drive improvements in Tegra's quality, resilience, and capacity, building upon strong customer demand for our products and ensuring our portfolio is well positioned for continued growth. I know Mojda is looking forward to introducing herself to you when she officially joins us in January. And now I'll turn it over to Jan and Leah to discuss our third quarter results.